A phase 3 study of VX-445 in triple combination with tezacaftor and VX-561 as a once-daily regimen in Subjects With Cystic Fibrosis in people with two copies of the F508del mutation (F508del/F508del).
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2018
At a glance
- Drugs VX 445 (Primary) ; Ivacaftor deuterated; Tezacaftor
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 03 Feb 2018 New trial record
- 31 Jan 2018 According to a Vertex Pharmaceuticals media release, company is discussing with regulatory authorities to finalise the design of this study. The study is expected to initiate in mid of 2018.